- Home
- PROP vs CGEN Comparison
PROP vs CGEN Comparison
Compare PROP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROP
- CGEN
- Stock Information
- Founded
- PROP 2001
- CGEN 1993
- Country
- PROP United States
- CGEN Israel
- Employees
- PROP N/A
- CGEN N/A
- Industry
- PROP Investment Bankers/Brokers/Service
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PROP Finance
- CGEN Health Care
- Exchange
- PROP Nasdaq
- CGEN Nasdaq
- Market Cap
- PROP 168.7M
- CGEN 167.4M
- IPO Year
- PROP N/A
- CGEN 2000
- Fundamental
- Price
- PROP $3.46
- CGEN $1.59
- Analyst Decision
- PROP Strong Buy
- CGEN
- Analyst Count
- PROP 5
- CGEN 0
- Target Price
- PROP $8.75
- CGEN N/A
- AVG Volume (30 Days)
- PROP 1.2M
- CGEN 155.0K
- Earning Date
- PROP 08-15-2025
- CGEN 08-05-2025
- Dividend Yield
- PROP N/A
- CGEN N/A
- EPS Growth
- PROP N/A
- CGEN N/A
- EPS
- PROP N/A
- CGEN N/A
- Revenue
- PROP $21,529,000.00
- CGEN $27,589,000.00
- Revenue This Year
- PROP $5,974.95
- CGEN N/A
- Revenue Next Year
- PROP $26.36
- CGEN $173.80
- P/E Ratio
- PROP N/A
- CGEN N/A
- Revenue Growth
- PROP N/A
- CGEN N/A
- 52 Week Low
- PROP $2.74
- CGEN $1.13
- 52 Week High
- PROP $12.30
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PROP 46.06
- CGEN 44.35
- Support Level
- PROP $3.30
- CGEN $1.66
- Resistance Level
- PROP $3.72
- CGEN $1.74
- Average True Range (ATR)
- PROP 0.27
- CGEN 0.10
- MACD
- PROP 0.03
- CGEN -0.02
- Stochastic Oscillator
- PROP 56.30
- CGEN 8.00
About PROP Prairie Operating Co.
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.